Opinion

Video

Advancing Multiple Myeloma Care: Insights From ASH 2024 and Beyond

Saad Z. Usmani, MD, MBA, FACP, discusses noteworthy data presented at ASH 2024, including the IFM2017-03 trial, and shares his excitement for ongoing research efforts in multiple myeloma, emphasizing key areas where further investigation is needed to improve patient outcomes and refine treatment strategies.

Video content above is prompted by the following:

  • Please discuss any other data in multiple myeloma released at ASH 2024 that you find noteworthy to share with colleagues.
  • Outside of ASH 2024, what ongoing research efforts are you most excited for in the treatment of multiple myeloma, and what are some key areas where you think further research is needed to continue improving patient outcomes?
Related Videos
5 experts are featured in this series.
5 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
1 expert is featured in this series.
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo